Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Psoriasis 1Periodic Fevers Syndrome 1Motor Activity 1Lymphoma, Follicular 1Crohn Disease 1Arthritis, Rheumatoid 1

Interventions

Rituximab 90Cyclophosphamide 30Lenalidomide 28Bendamustine Hydrochloride 24Prednisone 20Vincristine 19obinutuzumab 17Doxorubicin 16fludarabine 14ibrutinib 13tazemetostat 9idelalisib 9Deoxycholic Acid 9parsaclisib 8Prednisolone 8zanubrutinib 7venetoclax 7tofacitinib 7tisagenlecleucel 5pembrolizumab 5ofatumumab 5ibritumomab tiuxetan 5duvelisib 5Gemcitabine 5Bortezomib 5durvalumab 4aflibercept 4R-CHOP protocol 4Methylprednisolone 4Methotrexate 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, Follicular × secukinumab × Clear all
NCT00584740 2015-03-31

Efficacy, Safety and Tolerability of AIN457 in Moderate to Severe Active Crohn's Disease

Novartis

Phase 2 Terminated
59 enrolled 13 charts
Lymphoid

Crohn Disease, Lymphoma, Follicular, Motor Activity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡